索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]贾凌梅,陈亚丽.重组纽兰格林对心力衰竭治疗的研究进展[J].国际心血管病杂志,2018,01:31-34.
点击复制

重组纽兰格林对心力衰竭治疗的研究进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2018年01期
页码:
31-34
栏目:
综述
出版日期:
2018-01-25

文章信息/Info

Title:
-
作者:
贾凌梅; 陈亚丽
050051 河北医科大学第三医院
Author(s):
-
关键词:
重组纽兰格林;  心力衰竭;  治疗;  临床研究
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-534X.2018.01.009
文献标识码:
-
摘要:
纽兰格林-1是一种生长因子,在调控心脏发育和维持心脏功能方面发挥重要作用。多项动物及临床研究表明,补充外源性重组纽兰格林可持续改善左室收缩功能,逆转心室重构。
Abstract:
-

参考文献/References

[1] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Kardiol Pol, 2016, 74(10):1037-1147.
[2] Gu X, Liu X, Xu D, et al. Cardiac functional improvement in rats with myocardial infarction by up-regulating cardiac myosin light chain kinase with neuregulin[J]. Cardiovasc Res, 2010, 88(2):334-343.
[3] Marks AR. Calcium cycling proteins and heart failure: mechanisms and therapeutics[J]. J Clin Invest, 2013, 123(1):46-52.
[4] Brutsaert DL. Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity[J]. Physiol Rev, 2003, 83(1):59-115.
[5] Rupert CE, Coulombe KL. The roles of neuregulin-1 in cardiac development, homeostasis, and disease[J]. Biomark Insights, 2015, 10(Suppl 1):1-9.
[6] Lemmens K, Doggen K, De Keulenaer GW. Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure[J]. Circulation, 2007, 116(8):954-960.
[7] Gui C, Zhu L, Hu M, et al. Neuregulin-1/ErbB signaling is impaired in the rat model of diabetic cardiomyopathy[J]. Cardiovasc Pathol, 2012, 21(5):414-420.
[8] Rohrbach S, Niemann B, Silber RE, et al. Neuregulin receptors erbB2 and erbB4 in failing human myocardium-depressed expression and attenuated activation[J]. Basic Res Cardiol, 2005, 100(3):240-249.
[9] D’Uva G, Aharonov A, Lauriola M, et al. ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation[J]. Nat Cell Biol, 2015, 17(5):627-638.
[10] Iglesias-García O, Baumgartner S, Macrí-Pellizzeri L, et al. Neuregulin-1β induces mature ventricular cardiac differentiation from induced pluripotent stem cells contributing to cardiac tissue repair[J]. Stem Cells Dev, 2015, 24(4):484-496.
[11] Pentassuglia L, Heim P, Lebboukh S, et al. Neuregulin-1β promotes glucose uptake via PI3K/Akt in neonatal rat cardiomyocytes[J]. Am J Physiol Endocrinol Metab, 2016, 310(9):E782-E794.
[12] Gemberling M, Karra R, Dickson AL, et al. Nrg1 is an injury-induced cardiomyocyte mitogen for the endogenous heart regeneration program in zebrafish[J]. Elife, 2015, 4:e05871.
[13] Polizzotti BD, Ganapathy B, Walsh S, et al. Neuregulin stimulation of cardiomyocyte regeneration in mice and human myocardium reveals a therapeutic window[J]. Sci Transl Med, 2015, 7(281):281ra45.
[14] Guo YF, Zhang XX, Liu Y, et al. Neuregulin-1 attenuates mitochondrial dysfunction in a rat model of heart failure[J]. Chin Med J(Engl), 2012, 125(5):807-814.
[15] Li B, Zheng Z, Wei Y, et al. Therapeutic effects of neuregulin-1 in diabetic cardiomyopathy rats[J]. Cardiovasc Diabetol, 2011, 10(1):69.
[16] Gao R, Zhang J, Cheng L, et al. A phase Ⅱ, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure[J]. J Am Coll Cardiol, 2010, 55(18):1907-1914.
[17] Jabbour A, Hayward CS, Keogh AM, et al. Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses[J]. Eur J Heart Fail, 2011, 13(1):83-92.
[18] Hill MF, Patel AV, Murphy A, et al. Intravenous glial growth factor 2(GGF2)isoform of neuregulin-1β improves left ventricular function, gene and protein expression in rats after myocardial infarction[J]. PLoS One, 2013, 8(2):e55741.
[19] Parry TJ, Ganguly A, Troy EL, et al. Effects of neuregulin GGF2(cimaglermin alfa)dose and treatment frequency on left ventricular function in rats following myocardial infarction[J]. Eur J Pharmacol, 2017, 796:76-89.
[20] Lenihan DJ, Anderson SA, Lenneman CG, et al. A phase Ⅰ,single ascending dose study of cimaglermin Alfa(neuregulin 1β3)in patients with systolic dysfunction and heart failure[J]. Jacc Basic Transl Sci, 2016, 1(7):576-586.
[21] Longo DM, Generaux GT, Howell BA, et al. Refining liver safety risk assessment: application of mechanistic modeling and serum biomarkers to cimaglermin Alfa(GGF2)clinical trials[J]. Clin Pharmacol Ther, 2017, 102(6):961-969.
[22] Nanette H, Biahopric MD. A grawh tone for heart failure? [J]. Jacc Basic Transl Sci, 2016, 1(7):587-589.
[23] Jay SM, Murthy AC, Hawkins JF, et al. An engineered bivalent neuregulin protects against doxorubicin-induced cardiotoxicity with reduced proneoplastic potential[J]. Circulation, 2013, 128(2):152-161.

备注/Memo

备注/Memo:
通信作者:陈亚丽, Email:chenyalcn@aliyun.com
更新日期/Last Update: 2018-04-01